All Title Author
Keywords Abstract

Publish in OALib Journal
ISSN: 2333-9721
APC: Only $99


Screening of Single Nucleotide Polymorphism in CD95 (APO-1/FAS) Promoter Region (G-1377A) in Children with Acute Leukemia

DOI: 10.4236/oalib.1104385, PP. 1-7

Subject Areas: Hematology

Keywords: Acute Lymphoblastic Leukemia, Acute Myeloblastic Leukemia, CD 95 Polymorphism

Full-Text   Cite this paper   Add to My Lib


CD95 is a cell surface receptor involved in apoptotic signal transmission. Deregulation of this pathway results in down regulation of apoptosis and subsequent persistence of a malignant clone. A single nucleotide polymorphism (SNP) resulting in guanine-to-adenine (G > A) transition in the CD95 promoter region (position ﹣1377) is thought to reduce stimulatory protein 1 (SP1) transcription factor binding and decrease CD95 expression. The purpose of this study was to examine a genetic polymorphism in the core promoter of CD95 is associated with the frequency. G-1377A in the CD95 promoter region was genotyped by polymerase chain reaction and restriction endonuclease analysis and sequenced of the CD95 gene (Beckman Coulter, USA). Among 146 patients, CD95 G-1377A (rs2234767) SNP carriers frequencies has been identified as 25% GA (n:37) and AA 4% (n:6), respectively. This polymorphism of the distribution of the CD95 gene in acute leukemic children will be a guide for future studies.

Cite this paper

Bali, D. F. A. , Ozkan, D. T. , Kurekci, A. E. and Akar, N. (2018). Screening of Single Nucleotide Polymorphism in CD95 (APO-1/FAS) Promoter Region (G-1377A) in Children with Acute Leukemia. Open Access Library Journal, 5, e4385. doi:


[1]  Oehm, A., Behrmann, I., Falk, W., Pawlita, M., Maier, G., Klas, C., Li-Weber, M., Richards, S., Dhein, J., Trauth, B.C., et al. (1992) Purification and Molecular Cloning of the APO-1 Cell Surface Antigen, a Member of the Tumor Necrosis Factor/Nerve Growth Factor Receptor Superfamily. Sequence Identity with the Fas Antigen. Journal of Biological Chemistry, 267, 10709-10715.
[2]  Leithauser, F., Dhein, J. and Mechtersheimer, G. (1993) Constitutive and Induced Expression of APO-1, a New Member of the Nerve Growth Factor/Tumor Necrosis Factor Receptor Superfamily, in Normal and Neoplastic Cells. Laboratory Investigation, 69, 415-429.
[3]  Muschen, M., Warskulat, U. and Beckmann, M.W. (2000) Defining CD95 as a Tumor Suppressor Gene. Journal of Molecular Medicine, 78, 312-325.
[4]  Watanabe-Fukunaga, R., Brannan, C.I., Copeland, N.G., Jenkins, N.A. and Nagata, S. (1992) Lymphoproliferation Disorder in Mice Explained by Defects in Fas Antigen That Mediates Apoptosis. Nature, 356, 314-317.
[5]  Mehta, PA., Gerbing, R.B., Alonzo, T.A., Elliott, J.S., Zamzow, T.A., Combs, M., Stover, E., Ross, J.A., Perentesis, J.P., Meschinchi, S., Lange, B.J. and Davies, S.M. (2008) FAS Promoter Polymorphism: Outcome of Childhood Acute Myeloid Leukemia. A Children’s Oncology Group Report. Clinical Cancer Research, 14, 7896-7899.
[6]  Rieux-Laucat, F., Le Deist, F., Hivroz, C., Roberts, I.A., Debatin, K.M., Fischer, A. and de Villartay, J.P. (1995). Mutations in Fas Associated with Human Lymphoproliferative Syndrome and Autoimmunity. Science, 268, 1347-1349.
[7]  Owen-Schaub, L.B., Meterission, S. and Ford, R.J. (1993) Fas/APO-1 Expression and Function on Malignant Cells of Hematologic and Non-Hematologic Origin. Journal of Immunotherapy, 14, 234-241.
[8]  Debatin, K.M. and Krammer, P.H. (1995) Resistance to APO-1 (CD95) Induced Apoptosis in T-ALL Is Determined by a BCL-2 Independent Antiapoptotic Program. Leukemia, 9, 815.
[9]  Komada, Y., Zhou, Y.W., Zhang, X.L., Xue, H.L., Sakai, H., Tanaka, S., Sakatoku, H. and Sakurai, M. (1995) Fas Receptor (CD95)-Mediated Apoptosis Is Induced in Leukemic Cells Entering G1B Compartment of the Cell Cycle. Blood, 86, 3848-3860.
[10]  Beltinger, C., Kurz, E., Bohler, T., Schrappe, M., Ludwig, W.D. and Debatin, K.M. (1998) CD95 (APO-1/Fas) Mutations in Childhood T-Lineage Acute Lymphoblastic Leukemia. Blood, 91, 3943-3951.
[11]  Hu, Z., Li, C., Chen, K., Wang, L.E., Sturgis, E.M., Spitz, M.R. and Wei, Q. (2008) Single Nucleotide Polymorphisms in Selected Apoptotic Genes and BPDE-Induced Apoptotic Capacity in Apparently Normal Primary Lymphocytes: A Genotype-Phenotype Correla-tion Analysis. Journal of Cancer Epidemiology, 2008, Article ID: 147905.
[12]  Valibeigi, B., Amirghofran, Z., Golmoghaddam, H., Hajihosseini, R. and Kamazani, F.M. (2014) Fas Gene Variants in Childhood Acute Lymphoblastic Leukemia and Association with Prognosis. Pa-thology & Oncology Research, 20, 367-374.
[13]  Sibley, K., Rollinson, S., Allan, J.M., Smith, A.G., Law, G.R., Roddam, P.L., Skibola, C.F., Smith, M.T. and Morgan, G.J. (2003) Functional FAS Promoter Polymorphisms Are Associated with Increased Risk of Acute Myeloid Leukemia. Cancer Research, 63, 4327-4330.
[14]  Mata, J.F., Silveira, V.S., Mateo E.C., Cortez, M.A, Queiroz, R.G., Yunes, J.A. and Lee, M.L. (2010) Low mRNA Expression of the Apoptosis-Related Genes CASP3, CASP8, and FAS Is Associated with Low Induction Treatment Response in Childhood Acute Lymphoblastic Leukemia (ALL). Pediatric Blood & Cancer, 55, 100-107.
[15]  Baryshnikov, A., Polosukhina, E.R. and Tupitsin N.N. (1999) CD95 (FAS/APO-1) Antigen Is a New Prognostic Marker of Blast Cells of Acute Lymphoblastic Leukaemia Patients. Advances in Experimental Medicine and Biology, 457, 251-258.
[16]  Aref, S., Salama, O. and Al-Tonbary. Y. (2004) Assessment of Bcl-2 Expression as Modulator of Fas Mediated Apoptosis in Acute Leukemia. Hematology, 9, 113-121.
[17]  Wuchter, C., Karawajew, L. and Ruppert, V. (1999) Clinical Significance of CD95, Bcl-2 and Bax Expression and CD95 Function in Adult de Novo Acute Myeloid Leukemia in Context of P-Glycoprotein Function, Maturation Stage, and Cytogenetics. Leukemia, 13, 1943-1953.
[18]  Wuchter, C., Karawajew, L. and Ruppert, V. (2000) Constitutive Expression Levels of CD95 and Bcl-2 as Well as CD95 Function and Spontaneous Apoptosis in Vitro Do Not Predict the Response to Induction Chemotherapy and Relapse Rate in Childhood Acute Lymphoblastic Leukaemia. British Journal of Haematology, 110, 154-160.


comments powered by Disqus

Contact Us


微信:OALib Journal